With its listing on the New York Stock Exchange on May 4 and the conclusion of its initial public offering (IPO) on May 8, Kenvue (NYSE: KVUE) is finally a separate entity from Johnson Johnson (NYSE: JNJ).

The IPO raised net proceeds of $4.2 billion, and it marks the birth of a new giant within the consumer health products industry. And that may bring new opportunities for investors, too.

But consumer health goods businesses aren't exactly known for being fast-growing, and Kenvue still has a lot to prove now that it's standing on its own. So will this stock be a good fit for your portfolio? Let's investigate. 

Continue reading

Source Fool.com